{"entity":{"id":"nct07454187","kind":"trial","name":"To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma","aka":[],"tldr":"A phase 1/2 trial of SG2918 in multiple myeloma, run by Hangzhou Sumgen Biotech Co., Ltd., now recruiting.","summary":"To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT07454187 by Hangzhou Sumgen Biotech Co., Ltd., with 40 participants planned, started 2026-04-16 and due to reach its primary completion in 2027-09-30. Interventions recorded: SG2918.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07454187","url":"https://clinicaltrials.gov/study/NCT07454187"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["hangzhou-sumgen-biotech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07454187","phase":"1/2","setting":"A Phase 1b/2 Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SG2918 for Injection in Patients With Relapsed/Refractory Multiple Myeloma","sponsor":"Hangzhou Sumgen Biotech Co., Ltd.","enrolled":40,"outcomes":[]},"route":"/trials/nct07454187/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"company":[{"id":"hangzhou-sumgen-biotech","kind":"company","name":"Hangzhou Sumgen Biotech","route":"/companies/hangzhou-sumgen-biotech/"}]}}